Frederick, Md.-based NEOPATHOLOGY CORP., a company developing a new generation of tissue diagnostics and assays that are both highly accurate and rapidly delivered, recently received a $25,000 investment through TEDCO’s Pre-Seed Rural Business Innovation Initiative (RBII).

Paul Aiyetan, founder, CEO and director of NEOPATHOLOGY CORP., completed a regional I-Corps cohort in the summer of 2023, as well as an I-Corps Next cohort in August 2023. He was also a guest speaker during the 2024 I-Corps Next cohort.

TEDCO’s RBII was designed to enhance technology commercialization and provide technical and business assistance to small and early-stage companies based in rural Maryland.

“Our proprietary approach standardizes the tissue diagnostic process using contemporary spatial biology-enabling platforms,” said Aiyetan. “Through this process, we are hoping to reduce diagnostic errors, improve diagnostic accuracy and expedite the time to treatment initiation. Thanks to TEDCO’s investment, we can continue progressing towards our goals.”

NEOPATHOLOGY CORP.’s proprietary diagnostic process, ONEPATHOLOGY™, an end-to-end learning solution, seeks to standardize advanced spatial biology and contemporary deep-tissue profiling technologies utility and clinical adoption.

“Dr. Aiyetan’s innovative thinking proves why TEDCO’s RBII program exists–to further the research and development happening in rural Maryland,” said Karen Zuccardi, manager for TEDCO’s RBII. “We hope with this investment, NEOPATHOLOGY finds more success in bringing their platform to the market.”

Read the official TEDCO announcement here.